Skip to content


You currently have no items in your basket.

EMA Approved ATMPs 

Advanced Therapy Medicinal Products (ATMPs) approved by  European Medicines Agency (EMA).

Name Developer Indication Approval Date Status
Zynteglo Bluebird bio Feta-thalassemia Jun-19 Conditional Approved
Luxtuma Spark Therapeautics Retinal dystrophy Mar-19 Approved
Yescarta kite pharma B-cell lymphoma Aug-18 Approved
Alofisel TiGenix Perianal fistulas in Crihn's disease Mar-18 Approved
Spherox CO.DON Cartilage defects in the knee May-17 Approved
Zalmoxis MolMed Stem cell transplantation for blood cancer Jun-16 Approved
Strimvelis GSK ADA-SCID Apr-16 Approved
lmlygic Amgen Melanoma Oct-15 Approved
Holoclar Chiesi Limbal stem cell deficiency in the eyes Mar-15 Approved
Provenge Dendreon Metastatic prostate cancer Oct-13 Withdrawn in 2015
MAXI Vericel Cartilage defects in the knee Jul-13 Withdrawn in 2014
Glybera uniQure Lipoprotein lipase deficiency Nov-12 Withdrawn in 2017
Chondrocelect TiGenix Cartilage defects Nov-09 Withdrawn in 2016

To get a quote for the products or to place an order, please email